Insider Buying: Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Acquires 11,085 Shares of Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Steve Elms purchased 11,085 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the acquisition, the director now directly owns 325,370 shares in the company, valued at $1,041,184. The trade was a 3.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Marker Therapeutics Trading Down 0.3 %

NASDAQ:MRKR opened at $3.37 on Friday. Marker Therapeutics, Inc. has a twelve month low of $2.44 and a twelve month high of $6.16. The stock has a fifty day simple moving average of $3.72 and a 200-day simple moving average of $3.83.

Institutional Investors Weigh In On Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. grew its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 69,500 shares of the company’s stock after acquiring an additional 24,000 shares during the period. Wedbush Securities Inc. owned about 0.78% of Marker Therapeutics worth $377,000 at the end of the most recent quarter. 22.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH upped their target price on Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.